News
Matcha, the green tea packed with antioxidants, is often hailed as containing properties which prevent disease. Scientists in Salford, UK have shed a ray of light on the claim by testing it on cancer stem cells – with, they say, surprising results.

Matcha, the green tea packed with antioxidants, is often hailed as containing properties which prevent disease. Scientists in Salford, UK have shed a ray of light on the claim by testing it on cancer stem cells – with, they say, surprising results.
In research published in the journal Aging, a team from the Biomedical Research Centre at the University of Salford, used metabolic phenotyping on cell lines of breast cancer stem cells and found that Matcha “shifted cancer cells towards a quiescent metabolic state” and stopped their spread at a relatively low concentration (0.2 mg/ml).They also found that the signalling pathways that promote cancer stem cells indicated that Matcha “strongly affected mTOR signals, weakening components of the 40S ribosome. This raised the possibility that Matcha could be used in place of chemical drugs such as rapamycin.Michael Lisanti, professor of translational medicine at the centre, explained: “Matcha green tea is a natural product used as a dietary supplement with great potential for a range of treatments. But, the molecular mechanism underpinning all that remains largely unknown.“By using metabolic phenotyping, we found that the tea is suppressing oxidative mitochondrial metabolism – in other words it is preventing the cells from ‘re-fuelling’ and therefore they become inactive and die.“The effects on human breast cancer cells were very striking; the active ingredients in Matcha having a surgical effect in knocking out certain signalling pathways.“Our results are consistent with the idea that Matcha may have significant therapeutic potential, mediating the metabolic reprogramming of cancer cells.”The team, who specialise in identifying non-toxic methods of killing cancer stem cells, recently found that Earl Grey tea ingredient, Bergamot kills cancer cells and works as an anti-cholesterol agent.Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs) by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways is published in Aging and authored by Gloria Bonuccelli, Federica Sotgia and Michael P Lisanti.
2 Jul 2026
Today's global food system is fragile and volatile and governments must respond by building “resilient self-reliance”, says the think tank, IPES-Food.
Read more
24 Jun 2026
International dairy company Arla Foods and German farmer-owned business DMK Group are to merge, creating one of Europe’s biggest dairy cooperatives.
Read more
18 Jun 2026
Almost all plant-based food and drinks contain mycotoxins – naturally-occurring toxic compounds produced by fungi – and raw material monitoring should be extended, say researchers.
Read more
17 Jun 2026
Allergen-free food and drink products are now “structurally embedded” into the wider health and wellness category, with significant innovation happening at retail and brand level, say experts.
Read more
16 Jun 2026
With IFF set to sell its food ingredients division to CVC Capital Partners for €3.7 billion, we look at how mergers, acquisitions, and divestments are shaping the sector.
Read more
11 Jun 2026
US-based Healthy Eating Research has proposed an ingredient-based approach to defining ultra-processed foods (UPFs) to make them easier to identify for policy purposes.
Read more
10 Jun 2026
Many GLP-1 users have altered flavour preferences, becoming highly nuanced and “complex”, with important implications for how brands formulate, says the Institute of Grocery Distribution.
Read more
5 Jun 2026
US ingredients business Ingredion has made a £2.7bn takeover bid for its London-listed peer Tate & Lyle.
Read more
1 Jun 2026
Some of Europe’s biggest companies, including Coca-Cola, Kraft Heinz, McCormick, and Mondelēz, have called for new EU rules on packaging to be delayed.
Read more
28 May 2026
US front of pack nutrition labels are on the way – but policymakers and researchers are divided on how best to design them.
Read more